This session delves into the progress in diagnosing At-Risk-MASH, with discussions on the viability of achieving MASH resolution through drug development and the potential of non-invasive tests (NITs) for outcome prediction. The session also explores a Ph

University of California, San Francisco

University of Southern California

Duke University

Indiana University School of Medicine

The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine

Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland

Tampa General Hospital

Stanford University School of Medicine

National University Health System